Is it time to change the neurofibromatosis 1 diagnostic criteria?

National Institutes of Health Consensus Development Conference Statement, 1988, Neurofibromatosis, Arch Neurol (Chic), 45, 575, 10.1001/archneur.1988.00520290115023

Sabbagh, 2013, NF1 molecular characterization and neurofibromatosis type 1 genotype–phenotype correlation: the French experience, Hum Mutat, 34, 1510, 10.1002/humu.22392

Viskochil, 1990, Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus, Cell, 62, 187, 10.1016/0092-8674(90)90252-A

Trovó-Marqui, 2006, Neurofibromin: a general outlook, Clin Genet, 70, 1, 10.1111/j.1399-0004.2006.00639.x

Pasmant, 2010, NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype, Hum Mutat, 31, 1506, 10.1002/humu.21271

Upadhyaya, 2007, An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970–2972 delAAT): evidence of a clinically significant NF1 genotype–phenotype correlation, Am J Hum Genet, 80, 140, 10.1086/510781

Burkitt Wright, 2013, Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis, J Med Genet, 50, 606, 10.1136/jmedgenet-2013-101648

DeBella, 2000, Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children, Pediatrics, 105, 608, 10.1542/peds.105.3.608

Duong, 2011, Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: a cross-sectional study of 728 patients, Dermatology, 222, 269, 10.1159/000327379

Jouhilahti, 2011, The pathoetiology of neurofibromatosis 1, Am J Pathol, 178, 1932, 10.1016/j.ajpath.2010.12.056

Overdiek, 2008, Schwann cells from human neurofibromas show increased proliferation rates under the influence of progesterone, Pediatr Res, 64, 40, 10.1203/PDR.0b013e31817445b8

Abbas, 2010, Cutaneous plexiform lesions, J Cutan Pathol, 37, 613, 10.1111/j.1600-0560.2010.01529.x

Boyd, 2009, Neurofibromatosis type 1, J Am Acad Dermatol, 61, 1, 10.1016/j.jaad.2008.12.051

Cambiaghi, 2004, Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies, Pediatr Dermatol, 21, 97, 10.1111/j.0736-8046.2004.21201.x

Raygada, 2010, Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia, Pediatr Blood Cancer, 54, 173, 10.1002/pbc.22297

Zeller, 2002, Blue–red macules and pseudoatrophic macules in neurofibromatosis 1, Ann Dermatol Venereol, 129, 180

Yang, 2006, Nf1+/−mast cells induce neurofibroma like phenotypes through secreted TGF-β signaling, Hum Mol Genet, 15, 2421, 10.1093/hmg/ddl165

Brems, 2009, Glomus tumors in neurofibromatosis type 1: genetic, functional and clinical evidence of a novel association, Cancer Res, 69, 7393, 10.1158/0008-5472.CAN-09-1752

Tadini, 2013, Anemic nevus in neurofibromatosis type 1, Dermatology, 226, 115, 10.1159/000346643

Ragge, 1993, Images of Lisch nodules across the spectrum, Eye (Lond), 7, 95, 10.1038/eye.1993.20

Williamson, 1991, Structure of Lisch nodules in neurofibromatosis type 1, Ophthalmic Paediatr Genet, 12, 11, 10.3109/13816819109023079

Viola, 2012, Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1, Ophthalmology, 119, 369, 10.1016/j.ophtha.2011.07.046

Avery, 2011, Optic pathway gliomas, J Neuroophthalmol, 31, 269, 10.1097/WNO.0b013e31822aef82

Listernick, 2007, Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations, Ann Neurol, 61, 189, 10.1002/ana.21107

Avery, 2012, Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research, J Neurooncol, 110, 1, 10.1007/s11060-012-0944-y

Cassiman, 2013, Ophthalmological assessment of children with neurofibromatosis type 1, Eur J Pediatr, 172, 1327, 10.1007/s00431-013-2035-2

Armstrong, 2013, The generalized bone phenotype in children with neurofibromatosis 1: a sibling matched case–control study, Am J Med Genet A, 161, 1654, 10.1002/ajmg.a.36001

Arrington, 2013, Calvarial defects and skeletal dysplasia in patients with neurofibromatosis type 1, J Neurosurg Pediatr, 11, 410, 10.3171/2013.1.PEDS12409

Carmi, 1999, Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study, Pediatrics, 103, 1257, 10.1542/peds.103.6.1257

Sheng, 2007, Bone mineral density in children and adolescents with neurofibromatosis type 1, J Pediatr, 150, 83, 10.1016/j.jpeds.2006.10.048

Stevenson, 2011, Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1, J Pediatr Endocrinol Metab, 24, 169, 10.1515/jpem.2011.092

Hockett, 2013, Vitamin D status and muscle function in children with neurofibromatosis type 1 (NF1), J Musculoskelet Neuronal Interact, 13, 111

Lin, 2000, Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1, Am J Med Genet, 95, 108, 10.1002/1096-8628(20001113)95:2<108::AID-AJMG4>3.0.CO;2-0

Oderich, 2007, Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results, J Vasc Surg, 46, 475, 10.1016/j.jvs.2007.03.055

Han, 2005, Renal artery stenosis and aneurysms associated with neurofibromatosis, J Vasc Surg, 41, 539, 10.1016/j.jvs.2004.12.021

Margariti, 2007, Magnetization transfer ratio and volumetric analysis of the brain in macrocephalic patients with neurofibromatosis type 1, Eur Radiol, 17, 433, 10.1007/s00330-006-0323-1

Steen, 2001, Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities, Am J Neuroradiol, 22, 810

Gutmann, 2012, Neurofibromatosis type 1: modeling CNS dysfunction, J Neurosci, 32, 14087, 10.1523/JNEUROSCI.3242-12.2012

DeBella, 2000, Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children, Neurology, 54, 1646, 10.1212/WNL.54.8.1646

Hervey-Jumper, 2013, Diffuse pontine lesions in children with neurofibromatosis type 1: making a case for unidentified bright objects, Pediatr Neurosurg, 49, 55, 10.1159/000355417

Ostendorf, 2013, Epilepsy in individuals with neurofibromatosis type 1, Epilepsia, 54, 1810, 10.1111/epi.12348

Hsieh, 2011, Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects, Seizure, 20, 606, 10.1016/j.seizure.2011.04.016

Créange, 1999, Neurological complications of neurofibromatosis type 1 in adulthood, Brain, 122, 473, 10.1093/brain/122.3.473

Carotenuto, 2013, Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type 1, Neurol Sci, 34, 1905, 10.1007/s10072-013-1403-z

Hyman, 2005, The nature and frequency of cognitive deficits in children with neurofibromatosis type 1, Neurology, 65, 1037, 10.1212/01.wnl.0000179303.72345.ce

Lehtonen, 2013, Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence, Dev Med Child Neurol, 55, 111, 10.1111/j.1469-8749.2012.04399.x

Dilts, 1996, Children and adolescents with neurofibromatosis 1: a behavioral phenotype, J Dev Behav Pediatr, 17, 229, 10.1097/00004703-199608000-00004

Krab, 2008, Impact of neurofibromatosis type 1 on school performance, J Child Neurol, 23, 1002, 10.1177/0883073808316366

Garg, 2013, Neurofibromatosis type 1 and autism spectrum disorder, Pediatrics, 132, 1642, 10.1542/peds.2013-1868

Patil, 2012, Neoplasms associated with germline and somatic NF1 gene mutations, Oncologist, 17, 101, 10.1634/theoncologist.2010-0181

Seminog, 2013, Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study, Br J Cancer, 108, 193, 10.1038/bjc.2012.535

Van Lierde, 2013, Healthcare transition in patients with rare genetic disorders with and without developmental disability: neurofibromatosis 1 and Williams–Beuren syndrome, Am J Med Genet A, 161A, 1666, 10.1002/ajmg.a.35982

Lamm, 2014, Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors, Oncology, 86, 122, 10.1159/000357137

Granstrom, 2012, Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image, Dermatology, 224, 160, 10.1159/000337548

Merker, 2014, Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis, Am J Med Genet A, 10.1002/ajmg.a.36466

Evans, 2011, Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989, Eur J Hum Genet, 19, 1187, 10.1038/ejhg.2011.113

Widemann, 2014, CTF meeting 2012: translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies, Am J Med Genet A, 164, 563, 10.1002/ajmg.a.36312